{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:06:51Z","timestamp":1784754411937,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["GZB20230250"],"award-info":[{"award-number":["GZB20230250"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["CCNU25JC030"],"award-info":[{"award-number":["CCNU25JC030"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Hubei Province Natural Science Foundation","doi-asserted-by":"publisher","award":["2023AFB987"],"award-info":[{"award-number":["2023AFB987"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bioorg.2026.109603","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:15:46Z","timestamp":1770164146000},"page":"109603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of new non-macrocyclic TRK inhibitors based on conformational flexibility and scaffold hopping to overcome clinical acquired resistance"],"prefix":"10.1016","volume":"172","author":[{"given":"Zhong-Rui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Long","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Chuang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Qin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neng-Fang","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Can","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.109603_bb0005","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.neuro.24.1.677","article-title":"Neurotrophins: roles in neuronal development and function","volume":"24","author":"Huang","year":"2001","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.bioorg.2026.109603_bb0010","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1006\/jmbi.1999.2816","article-title":"Crystal structures of the Neurotrophin-binding domain of TrkA, TrkB and TrkC","volume":"290","author":"Ultsch","year":"1999","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bioorg.2026.109603_bb0015","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/43705","article-title":"Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor","volume":"401","author":"Wiesmann","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109603_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.593578","article-title":"NTRK fusions and TRK inhibitors: potential targeted therapies for adult glioblastoma","volume":"10","author":"Wang","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.109603_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117231","article-title":"Design, Synthesis and biological evaluation of novel 1H-indole-3-carbonitrile derivatives as potent TRK inhibitors","volume":"285","author":"Xu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109603_bb0030","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejmech.2019.04.053","article-title":"Targeting tropomyosin receptor kinase for Cancer therapy","volume":"175","author":"Miao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109603_bb0035","doi-asserted-by":"crossref","first-page":"14562","DOI":"10.1021\/acs.jmedchem.0c01342","article-title":"Discovery of first-in-class potent and selective tropomyosin receptor kinase degraders","volume":"63","author":"Chen","year":"2020","journal-title":"J. Med. Chem."},{"issue":"5005","key":"10.1016\/j.bioorg.2026.109603_bb0040","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1126\/science.1850549","article-title":"The trk proto-oncogene product: a signal transducing receptor for nerve growth factor","volume":"252","author":"Kaplan","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.109603_bb0045","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/350158a0","article-title":"Tyrosine phosphorylation and tyrosine kinase activity of the Trk proto-oncogene product induced by NGF","volume":"350","author":"Kaplan","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109603_bb0050","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0092-8674(91)90419-Y","article-title":"The Trk proto-oncogene encodes a receptor for nerve growth factor","volume":"65","author":"Klein","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.109603_bb0055","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/0092-8674(91)90442-2","article-title":"TrkC, a new member of the Trk family of tyrosine protein kinases, is a receptor for Neurotrophin-3","volume":"66","author":"Lamballe","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.109603_bb0060","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/0092-8674(91)90395-F","article-title":"TrkB encodes a functional receptor for brain-derived neurotrophic factor and Neurotrophin-3 but not nerve growth factor","volume":"65","author":"Squinto","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.109603_bb0065","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1006\/exnr.1999.7148","article-title":"Early BDNF, NT-3, and NT-4 signaling events","volume":"159","author":"Yuen","year":"1999","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bioorg.2026.109603_bb0070","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1039\/D2MD00334A","article-title":"Design, synthesis and biological evaluation of Pyrazolo[3,4-b]pyridine derivatives as TRK inhibitors","volume":"14","author":"Liu","year":"2023","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109603_bb0075","doi-asserted-by":"crossref","first-page":"15503","DOI":"10.1021\/acs.jmedchem.1c01539","article-title":"Discovery of next-generation tropomyosin receptor kinase inhibitors for combating multiple resistance associated with protein mutation","volume":"64","author":"Zhuo","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109603_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114096","article-title":"Rational drug design to explore the structure-activity relationship (SAR) of TRK inhibitors with 2,4-diaminopyrimidine scaffold","volume":"230","author":"Wu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109603_bb0085","article-title":"Efficacy and safety of Larotrectinib in patients with tropomyosin receptor kinase fusion\u2013positive lung cancers","volume":"6","author":"Drilon","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.bioorg.2026.109603_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112744","article-title":"Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants","volume":"207","author":"Wang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109603_bb0095","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1038\/ncomms5846","article-title":"The landscape of kinase fusions in Cancer","volume":"5","author":"Stransky","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.109603_bb0100","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2015-000023","article-title":"NTRK gene fusions as novel targets of cancer therapy across multiple tumour types","volume":"1","author":"Amatu","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.bioorg.2026.109603_bb0105","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1021\/acs.jmedchem.3c01645","article-title":"Discovery, optimization, and evaluation of novel Pyridin-2(1H)-one analogues as potent TRK inhibitors for Cancer treatment","volume":"67","author":"Xu","year":"2024","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109603_bb0110","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1210\/en.2002-221002","article-title":"The signaling adapters fibroblast growth factor receptor substrate 2 and 3 are activated by the thyroid TRK oncoproteins","volume":"144","author":"Ranzi","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.bioorg.2026.109603_bb0115","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.109603_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115291","article-title":"Design, synthesis and biological evaluation of novel Indolin-2-one derivatives as potent second-generation TRKs inhibitors","volume":"253","author":"Qin","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109603_bb0125","doi-asserted-by":"crossref","first-page":"e779","DOI":"10.1093\/oncolo\/oyac080","article-title":"Larotrectinib treatment for patients with TRK fusion-positive salivary gland cancers","volume":"29","author":"Le","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.bioorg.2026.109603_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113627","article-title":"Design, synthesis, biological evaluation and pharmacophore model analysis of novel tetrahydropyrrolo[3,4-c]pyrazol derivatives as potential TRKs inhibitors","volume":"223","author":"Wu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109603_bb0135","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.apsb.2020.05.004","article-title":"Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10.1016\/j.bioorg.2026.109603_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114654","article-title":"Discovery of 3-pyrazolyl-substituted pyrazolo[1,5-a]pyrimidine derivatives as potent TRK inhibitors to overcome clinically acquired resistance","volume":"241","author":"Gong","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109603_bb0145","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41416-024-02760-1","article-title":"Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents","volume":"131","author":"Roa","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.109603_bb0150","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1021\/acs.jmedchem.8b01092","article-title":"Insights into current tropomyosin receptor kinase (TRK) inhibitors: development and clinical application","volume":"62","author":"Yan","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109603_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103957","article-title":"NTRK fusions in thyroid cancer: pathology and clinical aspects","volume":"184","author":"Ma","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bioorg.2026.109603_bb0160","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1158\/2159-8290.CD-15-0443","article-title":"An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101","volume":"5","author":"Doebele","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.109603_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114451","article-title":"Discovery of quinazoline derivatives CZw-124 as a pan-TRK inhibitor with potent anticancer effects in vitro and in vivo","volume":"238","author":"Wu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109603_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114406","article-title":"Conformational adjustment overcomes multiple drug-resistance mutants of tropomyosin receptor kinase","volume":"237","author":"Mei","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109603_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115953","article-title":"Discovery of novel 3-(1H-pyrazol-4-yl)-1H-indazole derivatives as potent type II TRK inhibitors against acquired resistance","volume":"264","author":"Qin","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109603_bb0180","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/cncr.35036","article-title":"Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas","volume":"129","author":"Kummar","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2026.109603_bb0185","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.apsb.2023.11.010","article-title":"Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib","volume":"14","author":"Xiang","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2026.109603_bb0190","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2159-8290.CD-15-0940","article-title":"Acquired resistance to the TRK inhibitor Entrectinib in colorectal Cancer","volume":"6","author":"Russo","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.109603_bb0195","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1158\/2159-8290.CD-20-0571","article-title":"TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors","volume":"11","author":"Cocco","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.109603_bb0200","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/13543776.2024.2358818","article-title":"Type II & III Inhibitors of Tropomyosin Receptor Kinase (TRK): a 2020\u20132022 Patent Update","volume":"34","author":"Iliev","year":"2024","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2026.109603_bb0205","doi-asserted-by":"crossref","first-page":"10286","DOI":"10.1021\/acs.jmedchem.1c00712","article-title":"Discovery of the next-generation Pan-TRK kinase inhibitors for the treatment of Cancer","volume":"64","author":"Liu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109603_bb0210","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/2159-8290.CD-17-0507","article-title":"A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion\u2013Positive Solid Tumors","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.109603_bb0215","first-page":"viii23","article-title":"TRK inhibitors in TRK fusion-positive cancers, annals of","volume":"30","author":"Drilon","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109603_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114899","article-title":"Switch type I to type II TRK inhibitors for combating clinical resistance induced by xDFG mutation for cancer therapy","volume":"245","author":"Xiang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109603_bb0225","doi-asserted-by":"crossref","first-page":"12950","DOI":"10.1021\/acs.jmedchem.3c00899","article-title":"Structure-based optimization of the third generation type II macrocycle TRK inhibitors with improved activity against solvent-front, XDFG, and gatekeeper mutations","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109603_bb0230","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1021\/acs.jmedchem.2c00308","article-title":"Discovery of the first highly selective and broadly effective macrocycle-based type II TRK inhibitors that overcome clinically acquired resistance","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109603_bb0235","doi-asserted-by":"crossref","first-page":"bbac203","DOI":"10.1093\/bib\/bbac203","article-title":"Exploring the kinase-inhibitor fragment interaction space facilitates the discovery of kinase inhibitor overcoming resistance by mutations","volume":"23","author":"Wang","year":"2022","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.bioorg.2026.109603_bb0240","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/prot.10465","article-title":"Improved protein-ligand docking using GOLD","volume":"52","author":"Verdonk","year":"2003","journal-title":"Proteins"},{"key":"10.1016\/j.bioorg.2026.109603_bb0245","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1021\/jm301581y","article-title":"Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region\u2013Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance Against Imatinib","volume":"56","author":"Ren","year":"2013","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826001392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826001392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:58:07Z","timestamp":1784753887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826001392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":49,"alternative-id":["S0045206826001392"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109603","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of new non-macrocyclic TRK inhibitors based on conformational flexibility and scaffold hopping to overcome clinical acquired resistance","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109603","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109603"}}